Overview

A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-01-07

Target enrollment:

Participant gender:

Summary

This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Akeso

Treatments:

Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin